They found that in their cohort only the expression of PD-L1 by tumor cells correlated with both an objective response (as defined by the “Response evaluation criteria in Solid Tumors” or RECIST criteria) and clinical benefit (p = 0.025 and 0.005 respectively). Here, CD274 is linked to neoplasm.